Page last updated: 2024-09-05

erlotinib hydrochloride and Vulvar Neoplasms

erlotinib hydrochloride has been researched along with Vulvar Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Burandt, E; Coym, A; Hillen, C; Jaeger, A; Kuerti, S; Mathey, S; Mueller, V; Prieske, K; Schmalfeldt, B; Woelber, L	1
Bacha, OM; Lalancette, M; Levesque, E; Renaud, MC	1
Borger, DR; Brard, L; Dizon, DS; Growdon, WB; Horowitz, NS; Krasner, CN; Lee, J; Liu, JF; Matulonis, UA; Olawaiye, AB	1
Horowitz, N; Krasner, C; Lee, LM; Olawaiye, A	1

Reviews

1 review(s) available for erlotinib hydrochloride and Vulvar Neoplasms

Article	Year
Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature. Oncology research, 2021, Mar-16, Volume: 28, Issue:6 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vulvar Neoplasms	2021

Article

Year

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature.

Oncology research, 2021, Mar-16, Volume: 28, Issue:6

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vulvar Neoplasms

2021

Trials

1 trial(s) available for erlotinib hydrochloride and Vulvar Neoplasms

Article	Year
Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecologic oncology, 2012, Volume: 127, Issue:1 Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms	2012

Other Studies

2 other study(ies) available for erlotinib hydrochloride and Vulvar Neoplasms

Article	Year
A case of recurrent vulvar carcinoma treated with erlotinib, an EGFR inhibitor. European journal of gynaecological oncology, 2011, Volume: 32, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Quinazolines; Vulvar Neoplasms	2011
Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecologic oncology, 2007, Volume: 106, Issue:3 Topics: Aged; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vulvar Neoplasms	2007